Medication is sometimes necessary to treat eye conditions and vision problems. Of course, this is highly dependent on the ...
Susvimo 100 mg/mL for intravitreal use via ocular implant is a refillable implant surgically inserted into the eye during a ...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug ...
The new indication adds to the 2021 approval of Susvimo (ranibizumab) for 'wet' or neovascular age-related macular ...
Roche’s Susvimo, a refillable eye implant for diabetic macular edema, provides continuous delivery of ranibizumab, showing ...
The FDA has approved Susvimo (ranibizumab injection) for the treatment of patients with diabetic macular edema.
Seven months after the FDA signed off on a reintroduction of Roche’s eye implant Susvimo, the U.S. regulator has broadened ...
Colloidal drug aggregates prolong effect of glaucoma medicine up to seven weeks with a single, non-invasive injection ...
The results of this study show that the COVID-19 pandemic caused a notable drop in the number of common ophthalmic procedures among Medicare beneficiaries, especially in laser peripheral iridotomy, ...
Though complications rarely arise, they are often the result of the injection rather than the drug. They can include traumatic cataract, detached retina, increased eye pressure, and inflammation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback